Administração de metilprednisolona na esclerose multipla: revisão sistemática de literatura / Administration of methylprednisolone in multiple sclerosis: systematic literature review

Authors

  • Sarah Vitória Gomes de Sousa Brazilian Journals Publicações de Periódicos, São José dos Pinhais, Paraná
  • Salvador Viana Gomes Junior
  • Kellyson Lopes da Silva Macedo
  • Bruna Jéssica Dantas de Lucena
  • Lucas Emmanuel Rocha de Moura Marques
  • João Matheus Caé da Rocha
  • Francisco Emanoel Alves de Araújo
  • João Lindemberg Bandeira Lima

DOI:

https://doi.org/10.34117/bjdv7n3-073

Keywords:

Esclerose múltipla, Metilprednisolona, ensaio clínico.

Abstract

Introdução: Esclerose Múltipla (EM) constitui-se uma doença inflamatória desmielinizante, com incidências cada vez mais crescentes no mundo, demandando aumento nos gastos públicos com tratamentos. Dentre eles a aplicação da Metilprednisolona (MP) constitui-se uma prática clínica muito usada, contudo seus métodos de aplicação ainda não são definidos. Objetivos: O estudo constitui uma revisão sistemática de literatura com o objetivo de avaliar os efeitos da administração metilprednisolona na esclerose múltipla. Metodologia: Constitui-se de uma revisão da literatura nos bancos de dados do Science Direct e PubMed. Foram utilizados as estratégias de busca e os critérios de inclusão, logo, foram incluídos 10 estudos para constituição da revisão sistemática. Resultados e discussões: A MP demonstra resultados significativos como terapia na EM, principalmente quando administrada nos modos que utilizam uma alta dosagem do fármaco. Conclusão: A administração da MP demonstra ser eficaz no tratamento da EM, contudo ainda são necessários mais estudos para a determinação de parâmetros de dosagem, duração e número de aplicações.

 

 

References

ANLAR, Omer. Treatment of multiple sclerosis. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), v. 8, n. 3, p. 167-174, 2009. Disponível em: <https://www.ingentaconnect.com/content/ben/cnsnddt/2009/00000008/00000003/art00001>

BROCHET, Bruno et al. Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis. PloS one, v. 12, n. 1, p. e0168834, 2017. Disponível em: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0168834>

CASTER, Ola; EDWARDS, I. Ralph. Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. BMC neurology, v. 15, n. 1, p. 1-23, 2015. Disponível em: <https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-015-0450-x>

DORST, Johannes et al. Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial. EClinicalMedicine, v. 16, p. 98-106, 2019. Disponível em: <https://www.sciencedirect.com/science/article/pii/S2589537019302032>

DUBOIS, Bénédicte. Multiple sclerosis: from cure to care. Verhandelingen-Koninklijke Academie Voor Geneeskunde van Belgie, v. 71, n. 5, p. 295-300, 2009. Disponível em: <https://europepmc.org/article/med/20232785>

GRAU-LÓPEZ, L. et al. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses. Multiple Sclerosis Journal, v. 21, n. 5, p. 646-650, 2015. Disponível em: <https://journals.sagepub.com/doi/abs/10.1177/1352458514546786>

HERVÁS?GARCÍA, J. V. et al. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double?blind, non?inferiority trial. European journal of neurology, v. 26, n. 3, p. 525-532, 2019. Disponível em: <https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.13851>

JONGEN, Peter Joseph et al. Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. Journal of neurology, v. 263, n. 8, p. 1641-1651, 2016. Disponível em: <https://link.springer.com/article/10.1007/s00415-016-8183-3>

KAMM, Christian P.; UITDEHAAG, Bernard M.; POLMAN, Chris H. Multiple sclerosis: current knowledge and future outlook. European neurology, v. 72, n. 3-4, p. 132-141, 2014. Disponível em: <https://www.karger.com/Article/Abstract/360528>

KANHAI, K. M. S. et al. Glutathione?PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first?in?human study. British journal of clinical pharmacology, v. 84, n. 5, p. 1020-1028, 2018. Disponível em: <https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13525>

LE PAGE, Emmanuelle et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. The Lancet, v. 386, n. 9997, p. 974-981, 2015. Disponível em: <https://www.sciencedirect.com/science/article/abs/pii/S0140673615611370>

LIU, Shuo et al. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials. PloS one, v. 12, n. 11, p. e0188644, 2017. Disponível em: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0188644>

MYHR, K. M.; MELLGREN, S. I. Corticosteroids in the treatment of multiple sclerosis. Acta Neurologica Scandinavica, v. 120, p. 73-80, 2009. Disponível em: <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0404.2009.01213.x>

OHASHI, Takashi. Short-term high-dose intravenous methylprednisolone therapy. Nihon rinsho. Japanese journal of clinical medicine, v. 72, n. 11, p. 1995-1998, 2014. Disponível em: <https://europepmc.org/article/med/25518383>

ÖZAKBA?, Serkan et al. Monthly Pulse Methylprednisolone Therapy is Effective in Preventing Permanent Disease Progression in Secondary Progressive Multiple Sclerosis. Archives of Neuropsychiatry, v. 56, n. 2, p. 115, 2019. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563858/>

PREDI-MEDROL; Metilprednisolona. São Paulo: União Química, Reg. M.S.: 1.0497.1212. 2020.

RAMO-TELLO, Cristina et al. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses. Multiple Sclerosis Journal, v. 22, n. 1, p. 117-121, 2016. Disponível em: <https://journals.sagepub.com/doi/abs/10.1177/1352458515590648>

RATZER, Rikke et al. Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. Multiple Sclerosis Journal, v. 22, n. 7, p. 926-934, 2016. Disponível em: <https://journals.sagepub.com/doi/abs/10.1177/1352458515605908>

SEVEN, Arzu et al. Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy. Folia Neuropathologica, v. 51, n. 1, p. 58-64, 2013. Disponível em: <https://www.termedia.pl/Original-article-Evaluation-of-oxidative-and-nitrosative-stress-in-relapsing-remitting-multiple-sclerosis-effect-of-corticosteroid-therapy,20,20495,0,1.html>

VUKUSIC, Sandra et al. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD). Multiple sclerosis and related disorders, v. 29, p. 7-14, 2019. Disponível em: <https://www.sciencedirect.com/science/article/abs/pii/S2211034819300197>

WANG, Pin et al. Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis. European neurology, v. 72, n. 3-4, p. 249-254, 2014. Disponível em: <https://www.karger.com/Article/Abstract/363515>

Published

2021-03-04

How to Cite

de Sousa, S. V. G., Junior, S. V. G., Macedo, K. L. da S., de Lucena, B. J. D., Marques, L. E. R. de M., da Rocha, J. M. C., de Araújo, F. E. A., & Lima, J. L. B. (2021). Administração de metilprednisolona na esclerose multipla: revisão sistemática de literatura / Administration of methylprednisolone in multiple sclerosis: systematic literature review. Brazilian Journal of Development, 7(3), 21889–21904. https://doi.org/10.34117/bjdv7n3-073

Issue

Section

Original Papers